Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

BACKGROUND: The prognosis of patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer remains poor. Given the robust development of immunotherapy and targeted therapy during the last decades, we aimed to investigate if the combination of traditional second-line che...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Le, Wang, Weixue, Ge, Shaohua, Li, Hongli, Bai, Ming, Duan, Jingjing, Yang, Yuchong, Ning, Tao, Liu, Rui, Wang, Xia, Ji, Zhi, Wang, Feixue, Zhang, Haiyang, Ba, Yi, Deng, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985926/
https://www.ncbi.nlm.nih.gov/pubmed/36872337
http://dx.doi.org/10.1186/s12885-023-10661-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985926/
https://www.ncbi.nlm.nih.gov/pubmed/36872337
http://dx.doi.org/10.1186/s12885-023-10661-4

Ejemplares similares